# A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

> **NCT07179640** · PHASE1,PHASE2 · RECRUITING · sponsor: **Alesta Therapeutics** · enrollment: 120 (estimated)

## Conditions studied

- Hypophosphatasia (HPP)

## Interventions

- **DRUG:** ALE1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07179640
- **Lead sponsor:** Alesta Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07179640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07179640, "A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07179640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*